BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30860580)

  • 1. Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms.
    Vázquez-Borrego MC; Fuentes-Fayos AC; Herrera-Martínez AD; L-López F; Ibáñez-Costa A; Moreno-Moreno P; Alhambra-Expósito MR; Barrera-Martín A; Blanco-Acevedo C; Dios E; Venegas-Moreno E; Solivera J; Gahete MD; Soto-Moreno A; Gálvez-Moreno MA; Castaño JP; Luque RM
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3501-3513. PubMed ID: 30860580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors.
    Vázquez-Borrego MC; Fuentes-Fayos AC; Herrera-Martínez AD; Venegas-Moreno E; L-López F; Fanciulli A; Moreno-Moreno P; Alhambra-Expósito MR; Barrera-Martín A; Dios E; Blanco-Acevedo C; Solivera J; Granata R; Kineman RD; Gahete MD; Soto-Moreno A; Gálvez-Moreno MA; Castaño JP; Luque RM
    Neuroendocrinology; 2020; 110(11-12):1028-1041. PubMed ID: 31940630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells.
    Vázquez-Borrego MC; L-López F; Gálvez-Moreno MA; Fuentes-Fayos AC; Venegas-Moreno E; Herrera-Martínez AD; Blanco-Acevedo C; Solivera J; Landsman T; Gahete MD; Soto-Moreno A; Culler MD; Castaño JP; Luque RM
    Neuroendocrinology; 2020; 110(1-2):70-82. PubMed ID: 31272096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pituitary Gland is a Novel Major Site of Action of Metformin in Non-Human Primates: a Potential Path to Expand and Integrate Its Metabolic Actions.
    Vázquez-Borrego MC; Fuentes-Fayos AC; Gahete MD; Castaño JP; Kineman RD; Luque RM
    Cell Physiol Biochem; 2018; 49(4):1444-1459. PubMed ID: 30205369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Somatostatin Receptor Subtype-3 (SST
    Vázquez-Borrego MC; Gupta V; Ibáñez-Costa A; Gahete MD; Venegas-Moreno E; Toledano-Delgado Á; Cano DA; Blanco-Acevedo C; Ortega-Salas R; Japón MA; Barrera-Martín A; Vasiljevic A; Hill J; Zhang S; Halem H; Solivera J; Raverot G; Gálvez MA; Soto-Moreno A; Paez-Pereda M; Culler MD; Castaño JP; Luque RM
    Clin Cancer Res; 2020 Feb; 26(4):957-969. PubMed ID: 31624102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features.
    Vázquez-Borrego MC; Fuentes-Fayos AC; Venegas-Moreno E; Rivero-Cortés E; Dios E; Moreno-Moreno P; Madrazo-Atutxa A; Remón P; Solivera J; Wildemberg LE; Kasuki L; López-Fernández JM; Gadelha MR; Gálvez-Moreno MA; Soto-Moreno A; Gahete MD; Castaño JP; Luque RM
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31561558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Sáez-Martínez P; Gómez-Gómez E; León-González AJ; Fuentes-Fayos AC; Yubero-Serrano EM; Requena-Tapia MJ; López M; Castaño JP; Gahete MD; Luque RM
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e696-e710. PubMed ID: 33247590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation.
    Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.
    Mangili F; Esposito E; Treppiedi D; Catalano R; Marra G; Di Muro G; Barbieri AM; Locatelli M; Lania AG; Mangone A; Spada A; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2022; 13():867822. PubMed ID: 35721701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?
    Herrera-Martínez AD; Pedraza-Arevalo S; L-López F; Gahete MD; Gálvez-Moreno MA; Castaño JP; Luque RM
    J Clin Endocrinol Metab; 2019 Jan; 104(1):57-73. PubMed ID: 30265346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methyl succinate antagonises biguanide-induced AMPK-activation and death of pancreatic beta-cells through restoration of mitochondrial electron transfer.
    Hinke SA; Martens GA; Cai Y; Finsi J; Heimberg H; Pipeleers D; Van de Casteele M
    Br J Pharmacol; 2007 Apr; 150(8):1031-43. PubMed ID: 17339833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biguanides Metformin and Phenformin Generate Therapeutic Effects via AMP-Activated Protein Kinase/Extracellular-Regulated Kinase Pathways in an In Vitro Model of Graves' Orbitopathy.
    Han YE; Hwang S; Kim JH; Byun JW; Yoon JS; Lee EJ
    Thyroid; 2018 Apr; 28(4):528-536. PubMed ID: 29589999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs)].
    Nagamine T; Fukuda I
    No Shinkei Geka; 2023 Jul; 51(4):706-715. PubMed ID: 37491068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors.
    Mangili F; Giardino E; Treppiedi D; Barbieri AM; Catalano R; Locatelli M; Lania AG; Spada A; Arosio M; Mantovani G; Peverelli E
    Neuroendocrinology; 2021; 111(6):568-579. PubMed ID: 32512568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
    Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
    Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20 cells.
    Jin K; Ruan L; Pu J; Zhong A; Wang F; Tan S; Huang H; Mu J; Yang G
    Mol Cell Endocrinol; 2018 Dec; 478():53-61. PubMed ID: 30025915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
    Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
    J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenformin, But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia/Lymphoma via Cell-Autonomous AMPK Activation.
    Vara-Ciruelos D; Dandapani M; Russell FM; Grzes KM; Atrih A; Foretz M; Viollet B; Lamont DJ; Cantrell DA; Hardie DG
    Cell Rep; 2019 Apr; 27(3):690-698.e4. PubMed ID: 30995468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.